Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) was the recipient of a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 1,096,000 shares, an increase of 47.5% from the May 30th total of 742,800 shares. Based on an average trading volume of 189,100 shares, the short-interest ratio is presently 5.8 days. Approximately 5.5% of the company’s shares are sold short.
A number of hedge funds have recently added to or reduced their stakes in SNNA. Paloma Partners Management Co acquired a new stake in Sienna Biopharmaceuticals during the fourth quarter worth approximately $28,000. Dimensional Fund Advisors LP purchased a new stake in shares of Sienna Biopharmaceuticals during the 4th quarter worth $36,000. Rhumbline Advisers boosted its position in shares of Sienna Biopharmaceuticals by 52.9% during the 4th quarter. Rhumbline Advisers now owns 19,377 shares of the company’s stock worth $45,000 after purchasing an additional 6,702 shares in the last quarter. LLBH Private Wealth Management LLC purchased a new stake in shares of Sienna Biopharmaceuticals during the 1st quarter worth $49,000. Finally, Raymond James & Associates purchased a new stake in shares of Sienna Biopharmaceuticals during the 4th quarter worth $54,000. 51.32% of the stock is owned by institutional investors.
Several equities analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Garrett Motion from a “hold” rating to a “sell” rating in a research note on Wednesday, March 20th. JPMorgan Chase & Co. upped their price objective on shares of Vermilion Energy from C$42.00 to C$43.00 in a research note on Monday, May 13th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Sienna Biopharmaceuticals has a consensus rating of “Hold” and a consensus price target of $21.67.
Shares of NASDAQ:SNNA traded up $0.02 during midday trading on Friday, hitting $0.80. 618 shares of the stock traded hands, compared to its average volume of 220,828. The stock has a market cap of $24.13 million, a PE ratio of -0.22 and a beta of 2.90. The stock’s 50 day simple moving average is $1.07. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.61 and a quick ratio of 2.61. Sienna Biopharmaceuticals has a one year low of $0.72 and a one year high of $18.05.
Sienna Biopharmaceuticals (NASDAQ:SNNA) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.67) EPS for the quarter. Sell-side analysts expect that Sienna Biopharmaceuticals will post -1.93 earnings per share for the current year.
Sienna Biopharmaceuticals Company Profile
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Featured Article: Portfolio Manager
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.